Guideline on the clinical development of medicinal products for the treatment of cystic fibrosis

The aim of this guideline is to provide guidance on the clinical development of compounds for the treatment of cystic fibrosis, a systemic chronically debilitating disease, mainly paediatric up to now, with a regularly increasing adult population as life expectancy improves (47% adults in 2006 according to ECFS, mean-aged 16-22 yrs).

http://www.ema.europa.eu